Spain Set for Record Tourist Numbers in 2024 after First-Half Jump

FILE PHOTO: Tourists and residents drink on a street in Gracia neighborhood during a heatwave of the summer, in Barcelona, Spain August 19, 2023. REUTERS/Bruna Casas//File Photo
FILE PHOTO: Tourists and residents drink on a street in Gracia neighborhood during a heatwave of the summer, in Barcelona, Spain August 19, 2023. REUTERS/Bruna Casas//File Photo
TT

Spain Set for Record Tourist Numbers in 2024 after First-Half Jump

FILE PHOTO: Tourists and residents drink on a street in Gracia neighborhood during a heatwave of the summer, in Barcelona, Spain August 19, 2023. REUTERS/Bruna Casas//File Photo
FILE PHOTO: Tourists and residents drink on a street in Gracia neighborhood during a heatwave of the summer, in Barcelona, Spain August 19, 2023. REUTERS/Bruna Casas//File Photo

The number of foreign tourists in Spain jumped 13% in the first-half of 2024, putting the country on track for another record year for visitor numbers despite growing discontent over the impact of the holiday industry in some tourist hotspots.
For the six months to the end of June, 42.5 million international visitors arrived in Spain, with the month of June alone recording a 12% rise to 9 million as the busier summer period picks up, Spain's data agency INE reported on Friday.
That means 2024 is shaping up to be another record year for Spain, already the world's second most visited country behind France, making it likely it will beat last year's high of 85 million tourists, when numbers exceeded pre-pandemic levels, said Reuters.
But for some Spaniards in the most popular destinations including Mallorca, Barcelona and the Canary Islands, there is increasing unease about the influx of tourists and their impact on housing costs and locals have staged protests.
Earlier in July, a small group of anti-tourism campaigners in Barcelona squirted water pistols at foreign visitors, chanting "tourists go home", a demonstration that created headlines around the world.
Data showed that tourists spent 12.3 billion euros in Spain in June, 17% more than the same month last year, helping drive economic growth, but highlighting the challenge for a government trying to find the right balance between tourism and local interests.
A lack of affordable housing in Spain has been partly blamed on a boom in holiday lets on platforms such as Airbnb and Booking.com.
According to the data released on Friday, tourists are increasingly opting to stay in rented apartments. The number of visitors in the first-half of the year staying in that type of accommodation was up 30%, while those staying in hotels was up 11%.



Weight Loss Drug Cut Heart Failure Risk by 38% in Trial

An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City, US, December 11, 2023. REUTERS/Brendan McDermid/File Photo Purchase Licensing Rights
An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City, US, December 11, 2023. REUTERS/Brendan McDermid/File Photo Purchase Licensing Rights
TT

Weight Loss Drug Cut Heart Failure Risk by 38% in Trial

An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City, US, December 11, 2023. REUTERS/Brendan McDermid/File Photo Purchase Licensing Rights
An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City, US, December 11, 2023. REUTERS/Brendan McDermid/File Photo Purchase Licensing Rights

Trial results show Eli Lilly's weight loss drug Zepbound reduces the risk of hospitalization, death and other outcomes for obese adults with a common type of heart failure, the company said on Thursday as it continues to build a case for the medication's wider health benefits.

The drug, also known as tirzepatide, reduced the risk of a composite of heart failure urgent visit or hospitalization, oral diuretic intensification or cardiovascular death by 38% compared to a placebo, according to Reuters.

The trial enrolled 731 patients across 10 countries who have heart failure with preserved ejection fraction and obesity.

The condition "accounts for nearly half of all heart failure cases, and in the US almost 60% of those impacted also live with obesity," Jeff Emmick, Lilly senior vice president, product development, said in a statement.

Lilly said the study also showed the drug significantly improved heart failure symptoms and physical limitations.

Heart failure is a condition in which the heart is unable to pump enough blood to meet the body's needs. It is associated with a high burden of symptoms and physical limitations affecting daily life, including fatigue, shortness of breath, reduced ability to exercise and swelling of extremities.

Trial patients on tirzepatide were given weekly injections of the highest dose they could tolerate, up to 15 milligrams, and were followed for a median of two years.

The drug led to 15.7% weight loss in the combined population of people with and without type 2 diabetes, compared with 2.2% for the placebo, Lilly said. For the non-diabetes patients, weight loss was 13.9%.

Zepbound, also sold under the brand name Mounjaro for type 2 diabetes, is part of a top-selling class of drugs designed to mimic the action of the GLP-1 hormone, which helps regulate blood sugar, slow digestion and decrease appetite.

Lilly said the most common side effects for trial patients on tirzepatide were diarrhea, nausea, constipation and vomiting.

The company said it plans to submit the heart failure results to the US Food and Drug Administration and other regulatory agencies starting later this year. The findings will also be presented at an upcoming medical meeting and submitted to a peer-reviewed journal.

Novo Nordisk has reported data showing its GLP-1 weight loss drug Wegovy reduces heart failure symptoms.